Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT01449344 is registered in ClinicalTrials.gov with Prof. Dr. M. Dreyling (co-chairman) as lead sponsor.

NCT NCT01449344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01449344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Lead sponsor
Prof. Dr. M. Dreyling (co-chairman)
Phase
Phase 3
Overall status
Unknown status
Start date
May 9, 2009
Completion date
December 31, 2018
Enrollment
128 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma